Market open
TScan Therapeutics/$TCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Ticker
$TCRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
201
ISIN
US89854M1018
Website
TCRX Metrics
BasicAdvanced
$72M
-
-$2.32
1.06
-
Price and volume
Market cap
$72M
Beta
1.06
52-week high
$9.69
52-week low
$1.02
Average daily volume
424K
Financial strength
Current ratio
8.547
Quick ratio
8.441
Long term debt to equity
43.799
Total debt to equity
46.164
Interest coverage (TTM)
-41.42%
Management effectiveness
Return on assets (TTM)
-30.45%
Return on equity (TTM)
-78.93%
Valuation
Price to revenue (TTM)
16.385
Price to book
0.34
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-0.585
Growth
Revenue change (TTM)
-70.15%
Earnings per share change (TTM)
14.99%
3-year revenue growth (CAGR)
-26.50%
3-year earnings per share growth (CAGR)
-10.83%
What the Analysts think about TCRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for TScan Therapeutics stock.
TCRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TCRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TCRX News
AllArticlesVideos
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewsWire·2 weeks ago
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·1 month ago
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for TScan Therapeutics stock?
TScan Therapeutics (TCRX) has a market cap of $72M as of May 15, 2025.
What is the P/E ratio for TScan Therapeutics stock?
The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of May 15, 2025.
Does TScan Therapeutics stock pay dividends?
No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next TScan Therapeutics dividend payment date?
TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for TScan Therapeutics?
TScan Therapeutics (TCRX) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.